NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update
NuCana reported a Q2 2026 net loss of £3.1 million with cash and cash equivalents of £19.5 million, which management anticipates will fund operations into 2029. Patient recruitment is now complete in the Phase 2 NuTide:701 expansion study evaluating NUC-7738 in combination with pembrolizumab, with final data expected later in 2026.
Key figures
- Eps
- £0.00
- Cash runway
- into 2029
- Cash position
- £19.5 million
- Net loss 6m 2026
- £6.9 million
- Net loss q2 2026
- £3.1 million
- Rd expenses q2 2026
- £2.25 million
- Operating loss q2 2026
- £3.55 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.